Making sense of the evidence from the age-related eye disease study 2 randomized clinical trial

JAMA Ophthalmology

Volumn 132, Issue 8, 2014, Pages 1031-

  Downie, Laura Elizabeth ^a   Keller, Peter Richard ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PRACTICE; DIET SUPPLEMENTATION; DISEASE SEVERITY; EVIDENCE BASED MEDICINE; EVIDENCE BASED PRACTICE; HUMAN; LETTER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA AGE RELATED DEGENERATION; EXUDATIVE MACULAR DEGENERATION; FEMALE; MALE; NOTE;

XANTHOPHYLL;

FEMALE; HUMANS; LUTEIN; MALE; WET MACULAR DEGENERATION; XANTHOPHYLLS;

EID: 84905045619     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2014.2007     Document Type: Letter

References (3)

1. Musch DC. Evidence for including lutein and zeaxanthin in oral supplements for age-related macular degeneration. JAMA Ophthalmol. 2014;132(2):139-141.
2. Davis MD, Gangnon RE, Lee LY, et al; Age-Related Eye Disease Study Group. The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS report No. 17. Arch Ophthalmol. 2005;123(11):1484-1498.
3. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013;309(19): 2005-2015.